233 related articles for article (PubMed ID: 35786337)
1. An Appraisal on Synthetic and Medicinal Aspects of Fused Pyrimidines as Anti Neoplastic Agents.
Rani I; Kaur N; Goyal A; Sharma M
Anticancer Agents Med Chem; 2023; 23(5):525-561. PubMed ID: 35786337
[TBL] [Abstract][Full Text] [Related]
2. Anti-cancer pyrimidines in diverse scaffolds: a review of patent literature.
Kaur R; Kaur P; Sharma S; Singh G; Mehndiratta S; Bedi PM; Nepali K
Recent Pat Anticancer Drug Discov; 2015; 10(1):23-71. PubMed ID: 25230072
[TBL] [Abstract][Full Text] [Related]
3. FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
Wang S; Yuan XH; Wang SQ; Zhao W; Chen XB; Yu B
Eur J Med Chem; 2021 Mar; 214():113218. PubMed ID: 33540357
[TBL] [Abstract][Full Text] [Related]
4. Molecular Dynamics and Biological Evaluation of 2-chloro-7-cyclopentyl- 7H-pyrrolo[2,3-d]pyrimidine Derivatives Against Breast Cancer.
Singaram K; Marimuthu D; Baskaran S; Chinaga SK; Shanmugarajan D; Vadivel T
Comb Chem High Throughput Screen; 2017; 20(8):703-712. PubMed ID: 28738766
[TBL] [Abstract][Full Text] [Related]
5. Fused and Substituted Pyrimidine Derivatives as Profound Anti-Cancer Agents.
Abbas N; Matada GSP; Dhiwar PS; Patel S; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(7):861-893. PubMed ID: 32698738
[TBL] [Abstract][Full Text] [Related]
6. Pyrazolo - Pyrimidines as Targeted Anticancer Scaffolds - A Comprehensive Review.
Kandhasamy K; Surajambika RR; Velayudham PK
Med Chem; 2024; 20(3):293-310. PubMed ID: 37885114
[TBL] [Abstract][Full Text] [Related]
7. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
Arafa RK; Nour MS; El-Sayed NA
Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d]Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines.
Kilic-Kurt Z; Bakar-Ates F; Karakas B; Kütük Ö
Anticancer Agents Med Chem; 2018; 18(9):1303-1312. PubMed ID: 29866023
[TBL] [Abstract][Full Text] [Related]
9. Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery.
Li W; Zhang J; Wang M; Dong R; Zhou X; Zheng X; Sun L
Curr Top Med Chem; 2022 Mar; 22(4):284-304. PubMed ID: 35021973
[TBL] [Abstract][Full Text] [Related]
10. An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.
Cherukupalli S; Hampannavar GA; Chinnam S; Chandrasekaran B; Sayyad N; Kayamba F; Reddy Aleti R; Karpoormath R
Bioorg Med Chem; 2018 Jan; 26(2):309-339. PubMed ID: 29273417
[TBL] [Abstract][Full Text] [Related]
11. An Overview of the Synthetic Route to the Marketed Formulations of Pyrimidine: A Review.
Kumar A; Siwach A; Verma P
Mini Rev Med Chem; 2022; 22(6):884-903. PubMed ID: 34629043
[TBL] [Abstract][Full Text] [Related]
12. Pyrimidine: An elite heterocyclic leitmotif in drug discovery-synthesis and biological activity.
Nadar S; Khan T
Chem Biol Drug Des; 2022 Dec; 100(6):818-842. PubMed ID: 34914188
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic drug potential of oxazolo[5,4-d]pyrimidines and oxazolo[4,5-d]pyrimidines.
Zhirnov VV; Velihina YS; Mitiukhin OP; Brovarets VS
Chem Biol Drug Des; 2021 Oct; 98(4):561-581. PubMed ID: 34148293
[TBL] [Abstract][Full Text] [Related]
14. ZnO Nanoparticles Catalyst in the Synthesis of Bioactive Fused Pyrimidines as Anti-breast Cancer Agents Targeting VEGFR-2.
Dawood DH; Abbas EMH; Farghaly TA; Ali MM; Ibrahim MF
Med Chem; 2019; 15(3):277-286. PubMed ID: 30207239
[TBL] [Abstract][Full Text] [Related]
15. Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
Ali EMH; Abdel-Maksoud MS; Oh CH
Bioorg Med Chem; 2019 Apr; 27(7):1159-1194. PubMed ID: 30826188
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, Characterization, Antimicrobial Activity and Anticancer of Some New Pyrazolo[1,5-a]pyrimidines and Pyrazolo[5,1-c]1,2,4-triazines.
Hosny MA; Zaki YH; Mokbel WA; Abdelhamid AO
Med Chem; 2020; 16(6):750-760. PubMed ID: 31218963
[TBL] [Abstract][Full Text] [Related]
17. A Medicinal Chemist's Perspective Towards Structure Activity Relationship of Heterocycle Based Anticancer Agents.
Nehra B; Mathew B; Chawla PA
Curr Top Med Chem; 2022; 22(6):493-528. PubMed ID: 35021975
[TBL] [Abstract][Full Text] [Related]
18. An overview on synthetic and pharmaceutical prospective of pyrido[2,3-d]pyrimidines scaffold.
Yadav P; Shah K
Chem Biol Drug Des; 2021 Mar; 97(3):633-648. PubMed ID: 32946161
[TBL] [Abstract][Full Text] [Related]
19. Roles of Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Anticancer Agents.
Prachayasittikul S; Pingaew R; Worachartcheewan A; Sinthupoom N; Prachayasittikul V; Ruchirawat S; Prachayasittikul V
Mini Rev Med Chem; 2017; 17(10):869-901. PubMed ID: 27670581
[TBL] [Abstract][Full Text] [Related]
20. Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors.
Jadhav M; Sankhe K; Bhandare RR; Edis Z; Bloukh SH; Khan TA
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
